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Abstract
Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a
panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients
with or without chronic liver disease. Biomarkers and panels were assessed in a training group of consecutive patients
with chronic hepatitis C and B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were validated in two
independent groups including a prospective one. Steatosis was blindly assessed by using a previously validated scoring
system.
Results: 310 patients were included in the training group; 434 in three validation groups; and 140 in a control group.
SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest plus body mass index, serum
cholesterol, triglycerides, and glucose adjusted for age and gender. SteatoTest area under the ROC curves was 0.79 (SE
= 0.03) in the training group; 0.80 (0.04) in validation group 1; 0.86 (0.03) in validation group 2; and 0.72 (0.05) in the
validation group 3 – all significantly higher than the standard markers: γ-glutamyl-transpeptidase or alanine
aminotransferase. The median SteatoTest value was 0.13 in fasting controls; 0.16 in non-fasting controls; 0.31 in patients
without steatosis; 0.39 in grade 1 steatosis (0–5%); 0.58 in grade 2 (6–32%); and 0.74 in grade 3–4 (33–100%). For the
diagnosis of grade 2–4 steatosis, the sensitivity of SteatoTest at the 0.30 cut-off was 0.91, 0.98, 1.00 and 0.85 and the
specificity at the 0.70 cut-off was 0.89, 0.83, 0.92, 1.00, for the training and three validation groups, respectively.
Conclusion: SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need
for liver biopsy, particularly in patients with metabolic risk factor.
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Fatty liver or hepatic steatosis is defined as an excessive
accumulation of fat in hepatocytes [1]. On worldwide
grounds, the prevalence of steatosis is very high, and is
associated with several factors such as alcohol, diabetes,
overweight, hyperlipidemia, insulin resistance, hepatitis C
genotype 3, abetalipoproteinemia and administration of
some drugs [1-4].
Fatty liver disease involves the accumulation of triglycer-
ides in hepatocytes, apoptosis, hepatocellular ballooning,
Mallory's hyaline, necrosis of hepatocytes, lobular inflam-
mation [5,6], small hepatic vein obliteration [7] and often
fibrosis with possible progression to cirrhosis, hepatocel-
lular cancer and liver-related death [1,4,8,9].
Non-alcoholic fatty liver disease (NAFLD) is an adaptive
response of the liver to insulin resistance. The natural pro-
gression of insulin resistance and endogenous noxious
insults (such as free radical production, mitochondrial
dysfunction, endotoxin) which are, at least in part, related
to the presence of excessive fat in the liver, can trigger the
development of non-alcoholic steatohepatitis (NASH).
NASH itself can induce a fibrogenic response that can
result in cirrhosis [5,6].
In patients with alcoholic liver disease (ALD) [10,11],
chronic hepatitis C [12], and possibly in those with hepa-
titis B [13], the presence of steatosis is also associated with
fibrosis progression, with or without associated necroin-
flammatory lesions (alcoholic or viral hepatitis).
Current guidelines recommend liver biopsy as part of the
management of chronic liver disease [14]. This procedure
provides important information regarding the degree of
liver damage, in particular the severity of necroinflamma-
tory activity, fibrosis and steatosis [14]. Unfortunately,
liver biopsy has a potential sampling error, is invasive,
costly and prone to complications as well [15-19]. Up to
30% of patients experience pain following the procedure;
0.3% have severe complications; and mortality
approaches 0.01% [20,21].
As a result of those limitations as well as patient reluc-
tance to undergo liver biopsy, the estimate of liver injury
using non-invasive biomarkers has gained a growing
importance [20-22]. For the diagnosis of fibrosis, Fibro-
Test (FT) (Biopredictive, Paris France) has been validated
as a surrogate marker in chronic hepatitis C [23] and B
[24] and, recently, in ALD [25,26]. A preliminary study
has also observed a similar diagnostic value in NAFLD
[27]. ActiTest (AT) (Biopredictive, Paris France) has been
validated as a surrogate marker for necrosis in chronic
hepatitis C [23] and B [24]. Nonetheless, and despite
those tests, biopsy was still useful for the diagnosis of stea-
tosis and steatohepatitis.
For the diagnosis of steatosis, there is no standard recom-
mendation. The usual recommendation is to measure γ-
glutamyl-transpeptidase (GGT) and alanine aminotrans-
ferase (ALT) and, in addition, to perform liver biopsy for
grading and staging [1,3,4,14]. The evaluation of liver
steatosis using ultrasonography is subjective as based on
echo intensity (echogenicity) and special patterns of ech-
oes (texture) and is inaccurate in patients with advanced
fibrosis [28]. Up to now, no study has demonstrated that
a single or a panel of biomarkers can be used as an alter-
native to liver biopsy for the diagnosis of steatosis,
whether induced by alcohol, viral hepatitis or NAFLD, the
most common causes of steatosis.
The objective of the current study was to create a new
panel of biomarkers known as SteatoTest (ST) with suffi-
cient predictive values for the diagnosis of steatosis due to
alcohol, NAFLD and hepatitis C and B. Serum GGT and




A total of 2,272 subjects were analyzed (Figure 1), being
884 subjects included in the biomarker validation study,
distributed as follows: 310 patients in the training group;
171 in the validation group 1; 201 in the validation group
2; 62 in the validation group 3; and 140 subjects in the
control group. The 1,388 non-included patients were not
significantly different from the 884 patients integrated in
the validation assay (data not shown).
Comparison between groups (Table 1)
Patients included in the 4 groups were similar in age with
a predominance of male subjects (range 61–76%). The
prevalence of steatosis greater than 5% (grades 2 to 4) var-
ied from 11% in hepatitis C virus (HCV) cured patients to
94% in patients with ALD. In all groups, at least one met-
abolic risk factor was observed in more than 50% of
included patients. Patients in group 3 with alcoholic liver
disease were more often male, older, had smaller liver
biopsies, more metabolic risk factors, more extensive
fibrosis and more grades 2–4 steatosis than the three other
groups. Validation group 2 with HCV cured patients had
quasi-normal characteristics with normal liver tests and
only 11% grade 2–4 steatosis.
Factors associated with steatosis (Table 2)
In the training group the most significant components
associated with the presence of grade 2–4 steatosis in uni-
variate analysis were body mass index (BMI), age, ALT,
aspartate aminotransferase (AST), GGT, glucose, and trig-Page 2 of 14
(page number not for citation purposes)
Comparative Hepatology 2005, 4:10 http://www.comparative-hepatology.com/content/4/1/10lycerides. The logistic regression defining the ST included
12 components – ALT, α2-macroglobulin (A2M), apolipo-
protein A-I (ApoA1), haptoglobin, total bilirubin, GGT,
cholesterol, triglycerides, glucose, age, gender and BMI. In
logistic regression analyses, the most significant compo-
nents were BMI (P = 0.0002), GGT (P = 0.002), ApoA1 (P
= 0.01), A2M (P = 0.02), ALT (P = 0.03) and triglycerides
(P = 0.04). In the validation group, similar differences
were observed, most significantly for BMI, GGT, ALT and
triglycerides (Table 2).
Distribution of SteatoTest according to steatosis grades 
(Figure 2)
The median ST value was 0.13 in fasting controls; 0.18 in
non-fasting controls; 0.14 in blood donors; 0.26 in
patients without steatosis; 0.43 in grade 1 steatosis; 0.62
in grade 2; 0.70 in grade 3; and 0.75 in grade 4. Because
there were not a sufficient number of patients with grade
3 and 4, these two groups were combined (Figure 2).
Diagnostic value of SteatoTest (Tables 3 and 4)
The values {Area under the ROC curves (AUROCs)} of ST,
GGT and ALT for the diagnosis of grades 2–4 steatosis, in
the training and validation groups, are given in Table 3. ST
had higher AUROCs: {0.79 (SE = 0.03)} in training
group; 0.80 (0.04) in validation group 1; 0.86 (0.03) in
validation group 2; and 0.72 (0.05) in validation group 3.
These were always significantly higher than the AUROCs
of GGT and significantly higher than the AUROCs of ALT,
for the training group and validation group 1 (Table 3).
The distribution of ST, GGT and ALT, according to the
severity of steatosis, is illustrated in Figure 2 for the train-
ing and validation groups.
The diagnostic values of ST, GGT and ALT according to
cutoffs are shown in Table 4. For the diagnosis of grade 2–
4 steatosis, the sensitivity of ST at the 0.30 cut-off was
0.91, 0.98, 1.00 and 0.85 and the specificity at the 0.70
cut-off was 0.89, 0.83, 0.92, and 1.00, for the training and
validation groups, respectively.
In the training group, there were 56 cases (18%) of signif-
icant discordance between steatosis percentage as pre-
dicted by ST and that observed in biopsy samples. Failure
attributable to ST (false positive of ST) was suspected in
one case that had acute drug hepatitis associated with
chronic hepatitis B. Failure attributable to biopsy (false
negatives of biopsy) was suspected in 16 cases with poor
quality biopsy samples (median length 13 mm, 2 frag-
ments) and, at least, one metabolic risk factor. For the val-
Flow chart of patients analyzed and included in the training and validation groupsigure 1
Flow chart of patients analyzed and included in the training and validation groups.
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Table 1: Characteristics of the patients.
Characteristics Training
group
Validation Group 1 – 
HCV before treatment
Validation Group 2 – 
HCV sustained 
responders
Validation Group 3 – 
Alcoholic liver
disease
Number of patients 310 171 201 62
Age at biopsy, years 48.9 (12.4) 44.1 (7.2) 43.6 (8.0) 46.6 (9.8)
Male 201 (65%) 111 (65%) 122 (61%) 47/62 (76%)
Female 109 (35%) 60 (35%) 79 (39%) 15 (24%)
BMI, kg/m2 25.4 (5.1) 27.7 (5.0) 26.5 (4.8) 24.2 (4.1)
Biopsy quality
Length 17.0 (6.2) 16.6 (15.5) 17.0 (8.2) 13.5 (6.8)
Length ≥ 15 mm 205 (67%) 82 (48%) 96 (48%) 15 (24%)
Number of fragments 2.5 (2.3) - - 1.9 (1.6)
One fragment 128/278 (46%) - - 37 (60%)
Duration biopsy-serum, mean (days range) 1 (0–30) 40 (0–90) 11 (0–45) 7 (0–14)
Liver Risk factor
HCV 211 (68%) 171 (100%) 0 (0%) 0 (0%)
HBV 18 (6%) 0 (0%) 0 (0%) 0 (0%)
NAFLD 69 (22%) 0 (0%) 0 (0%) 0 (0%)
ALD 12 (4%) 0 (0%) 0 (0%) 0 (0%)
Daily alcohol = 50 g/day 34/236 (14%) 0 (0%) 0 (0%) 62 (100%)
Cured HCV infection 0 (0%) 0 (0%) 201 (100%) 0 (0%)
Metabolic factor
BMI ≥ 27.0 92 (30%) 88 (51%) 77 (38%) 14 (23%)
Glucose ≥ 6.0 mmol/L 63 (20%) 30 (18%) 27 (13%) 20 (32%)
Triglycerides ≥ 1.7 mmol/L 67 (22%) 36 (21%) 54 (27%) 20 (32%)
Cholesterol ≥ 6.0 mmol/L 61 (20%) 12 (7%) 26 (13%) 23 (37%)
Metabolic factor: number per patient
None 132 (43%) 60 (35%) 96 (48%) 17 (27%)
One 101 (33%) 64 (37%) 72 (36%) 20 (32%)
Two 52 (17%) 39 (23%) 31 (15%) 19 (31%)
Three 22 (7%) 8 (5%) 0 (0%) 5 (8%)
Four 3 (1%) 0 (0%) 2 (1%) 1 (2%)
Liver steatosis grade
None (0%) 130 (42%) 58 (34%) 116 (58%) 2 (3%)
Mild (Score 1–5%) 40 (13%) 68 (40%) 63 (31%) 2 (3%)
Moderate (Score 6–33%) 69 (22%) 35 (20%) 17 (8%) 42 (68%)
Marked (Score 34–66%) 36 (12%) 7 (4%) 4 (3%) 12 (19%)
Severe (Score 67–100%) 35 (11%) 3 (2%) 1 (0.5%) 4 (7%)
Liver fibrosis stage at biopsy
F0 – No fibrosis 62 (20%) 0 (0%) 16 (8%) 8 (13%)
F1 – Fibrosis without septa 127 (41%) 102 (60%) 136 (68%) 23 (37%)
F2 – Few septa 52 (17%) 39 (23%) 33 (16%) 11 (18%)
F3 – Many septa 36 (11%) 19 (11%) 9 (4%) 7 (11%)
F4 – Cirrhosis 33 (11%) 11 (6%) 7 (3%) 13 (21%)
Markers (normal range)
AST, IU/L (17–27 female; 20–32 male) 83 (159) 82 (57) 23 (9) 89 (83)
ALT, IU/L (11–26 female; 16–35 male) 109 (114) 118 (94) 19 (10) 72 (88)
Total bilirubin, mol/L (1–21) 14.8 (26.2) 11.1 (4.8) 8.8 (4.6) 21.5 (19.6)
GGT, U/L (7–32 female; 11–49 male) 112 (183) 84 (96) 21 (18) 323 (443)
A2M, g/L (female 1·6-4·0; male 1·4-3·3) 2.4 (1.0) 3.1 (1.2) 2.0 (0.8) 1.8 (0.5)
ApoA1 g/L (1·2-1·7) 1.4 (0.3) 1.3 (0.3) 1.2 (0.3) 1.5 (0.5)
Haptoglobin, g/L (0·35-2·00)* 0.95 (0.57) 0.78 (0.45) 0.86 (0.43) 1.39 (0.63)
Glucose, mmol/L 5.5 (3.2) 5.4 (1.2) 5.3 (1.0) 5.8 (1.6)
Cholesterol, mmol/L 4.9 (1.3) 4.5 (1.0) 5.0 (1.0) 5.4 (1.9)
Triglycerides, mmol/L 1.5 (1.4) 1.4 (0.8) 1.6 (1.0) 1.9 (3.1)
FibroTest 0.42 (0.28) 0.47 (0.26) 0.29 (0.20) 0.43 (0.28)
SteatoTest 0.49 (0.25) 0.53 (0.22) 0.36 (0.22) 0.58 (0.25)
Data are mean (SD) or proportion. BMI = body mass index; HCV = hepatitis C virus; HBV = hepatitis B virus; NAFLD = non-alcoholic fatty liver 
disease; ALD = alcoholic liver disease; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = γ-glutamyl transpeptidase; A2M = 
α2-macroglobulin; ApoA1 = apolipoprotein A1.
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Characteristic Steatosis Training Group Steatosis Validation Group 1 – HCV before 
treatment
< 5%, n = 170 ≥ 5%, n = 140 P value No, n = 126 Yes, n = 45 P value
Demographics
Age at biopsy, years 46.7 (12.4) 51.8 (12.1) 0.0004 43.7 (7.3) 45.2 (7.0) 0.28
Male gender 110 (55%) 91 (45%) 0.96 81 (64%) 30 (67%) 0.77
BMI 24 (4) 27 (6) < 0.0001 27 (5) 31 (4) < 0.0001
Biochemical markers
α2-macroglobulin, g/L 2.47 (1.00) 2.30 (1.04) 0.07 3.10 (1.23) 3.20 (1.24) 0.50
ALT, IU/L 104 (119) 115 (108) 0.02 46 (45) 61 (48) 0.003
AST, IU/L 83 (204) 83 (78) 0.01 80 (61) 88 (43) 0.01
Apolipoprotein A1, g/L 1.46 (0.34) 1.42 (0.33) 0.30 1.27 (0.26) 1.20 (0.24) 0.18
Haptoglobin, g/L 0.93 (0.60) 0.96 (0.52) 0.19 0.77 (0.45) 0.78 (0.44) 0.84
GGT, IU/L 83 (132) 147 (226) < 0.0001 72 (85) 118 (116) 0.0007
Total bilirubin, µmol/L 14.8 (31.4) 14.7 (17.8) 0.47 11.0 (5.0) 11.3 (4.1) 0.38
Glucose mmol/L 5.1 (3.7) 5.9 (2.2) < 0.0001 5.2 (0.9) 6.0 (1.8) 0.0007
Triglycerides, mmol/L 1.24 (0.95) 1.88 (1.78) < 0.0001 1.26 (0.72) 1.72 (1.0) 0.0008
Total cholesterol, mmol/L 4.8 (1.2) 5.1 (1.4) 0.10 4.5 (1.0) 4.4 (1.0) 0.10
FibroTest 0.40 (0.29) 0.45 (0.28) 0.47 0.45 (0.26) 0.53 (0.24) 0.07
SteatoTest 0.38 (0.21) 0.62 (0.22) < 0.0001 0.47 (0.21) 0.70 (0.16) < 0.0001
Characteristic Steatosis Validation Group 2 – HCV sustained 
responders
Steatosis Validation Group 3 – Alcoholic liver 
disease
No n = 179 Yes n = 22 P value < 5%, n = 4 ≥ 5%, n = 58 P value
Demographics
Age at biopsy, years 43.7 (8.1) 43.1 (7.0) 0.7 38.0 (12.8) 47 (9.4) 0.16
Male gender 110 (62%) 12 (55%) 0.53 2 (50%) 45 (78%) 0.21
BMI 26 (4) 31 (6) <0.0001 22.9 (2.9) 24.3 (4.2) 0.49
Biochemical markers
α2-macroglobulin, g/L 2.08 (0.79) 1.73 (0.66) 0.06 2.12 (0.53) 1.81 (0.55) 0.26
ALT, IU/L 18 (9) 26 (9) <0.0001 35 (24) 74 (90) 0.10
AST, IU/L 23 (9) 25 (7) 0.06 74 (43) 58 (90) 1.00
Apolipoprotein A1, g/L 1.16 (0.28) 1.07 (0.25) 0.2 1.67 (0.43) 1.48 (0.49) 0.49
Haptoglobin, g/L 0.85 (0.41) 0.94 (0.56) 0.85 1.55 (0.92) 1.38 (0.62) 0.85
GGT, IU/L 20 (18) 28 (14) 0.0002 327 (184) 323 (323) 0.41
Total bilirubin, µmol/L 8.9 (4.6) 8.1 (4.3) 0.3 28.5 (23.4) 21.1 (19.5) 0.28
Glucose, mmol/L 5.3 (1.0) 5.5 (0.8) 0.16 6.5 (2.2) 5.7 (1.6) 0.46
Triglycerides, mmol/L 1.49 (0.98) 2.05 (1.22) 0.003 1.05 (0.51) 1.96 (3.15) 0.28
Total cholesterol, mmol/L 5.0 (1.0) 5.1 (0.9) 0.51 6.0 (1.38) 5.4 (2.0) 0.68
FibroTest 0.29 (0.20) 0.26 (0.19) 0.46 0.43 (0.32) 0.43 (0.28) 0.79
SteatoTest 0.32 (0.20) 0.62 (0.17) <0.0001 0.44 (0.03) 0.59 (0.26) 0.21
Data are mean (SD) or proportion.
idation' groups, significant discordance was observed in
17 cases (16%) in group 1; 20 cases (10%) in group 2; and
13 cases (21%) in group 3. Significant discordance was
observed more often in patients with extensive fibrosis
(stage F3 or F4): 38 cases out of 135 (28%) versus 91 cases
out of 609 (15%) – P = 0.001.
Repeated biopsies and repeated SteatoTest
A total of 75 patients were included with biopsy at base-
line and at follow-up. Among them, 23 had an improve-
ment of steatosis (one of 3 grades, two of 2 grades and
twenty of one grade); 43 had no change in steatosis grade;
and 9 had worsening of one grade. ST significantly
decreased in 23 patients with steatosis improvement at
biopsy from 0.60 (SE = 0.05) to 0.41 (0.05), a signifi-
cantly greater difference (P = 0.001) than that observed in
52 patients without biopsy improvement: from 0.44
(0.03) to 0.31 (0.03).
Integrated database
A total of 884 subjects were included in the integrated
database combining the training group, the three valida-Page 5 of 14
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Relationship between ST, GGT and ALT and the grade of liver steatosisFigure 2
Relationship between ST, GGT and ALT and the grade of liver steatosis. A four grades scoring system was used to 
assess steatosis: S0 – no steatosis; S1 – mild, 1 to 5%; S2 – moderate, 6 to 32%; S3-S4 – marked or severe, 33 to 100%. 
Notched box plots showing the relationship (A) in the training group; (B) in validation group 1, HCV patients before treatment; 
(C) group 2, HCV sustained responders; (D) group 3, alcoholic liver disease; and (E) in controls, healthy volunteers fasting and 
non-fasting and non-fasting blood donors. The horizontal line inside each box represents the median and the width of each box 
the median ± 1.57 interquartile range/vn for assessing the 95% level of significance between group medians. Failure of the 
shaded boxes to overlap corresponds to statistical significance (P < 0.05). The horizontal lines above and below each box 
encompass the interquartile range (from 25th to 75th percentile), and the vertical lines from the ends of the box encompass the 
adjacent values (upper: 75th percentile plus 1.5 times interquartile range, lower 25th percentile minus 1.5 times interquartile 















































































































































































































































Comparative Hepatology 2005, 4:10 http://www.comparative-hepatology.com/content/4/1/10tion groups and the control group. Of these, 75 patients
with HCV were investigated twice (once before and then
after treatment), and 29 volunteers were investigated
twice (while fasting and, then, non-fasting). There was a
very significant overall correlation between ST and the
steatosis grades from controls to S3 (Figure 3). For ST,
there was a significant difference between all histological
grades by Tukey-Kramer multiple comparison test for all
pairwise differences between means (P < 0.05). For GGT
and ALT, there was no significant difference between S0
and S1. For ALT, there was no significant difference
between S0 and S2, S1 and S2, and S2 and S3, either. ST
has higher AUROC, 0.80 (0.02) than all the isolated com-
ponents for the diagnosis of steatosis grade 2–4: ALT, GGT
Table 4: Diagnostic value of SteatoTest for predicting liver steatosis greater than 5%.




Training Group N = 310 Prevalence = 45%
SteatoTest 0.30 0.91 (127/140) 0.45 (77/170) 0.58 (127/220) 0.86 (77/90)
SteatoTest 0.50 0.69 (97/140) 0.74 (126/170) 0.69 (97/141) 0.75 (126/169)
SteatoTest 0.70 0.45 (63/140) 0.89 (152/170) 0.78 (63/81) 0.66 (152/229)
GGT 50 IU/L 0.66 (92/140) 0.55 (94/170) 0.55 (92/168) 0.66 (94/142)
ALT 50 IU/L 0.77 (108/140) 0.35 (60/170) 0.50 (108/218) 0.65 (60/92)
Validation Group1 N = 
171
Prevalence = 26%
SteatoTest 0.30 0.98 (44/45) 0.24 (30/126) 0.31 (44/140) 0.97 (30/31)
SteatoTest 0.50 0.89 (40/45) 0.58 (73/126) 0.43 (40/93) 0.94 (73/78)
SteatoTest 0.70 0.44 (20/45) 0.83 (105/126) 0.49 (20/41) 0.81 (105/130)
GGT 50 IU/L 0.62 (28/45) 0.61 (72/126) 0.34 (28/82) 0.81 (72/89)
ALT 50 IU/L 1.00 (45/45) 0.06 (8/126) 0.28 (45/163) 1.00 (8/8)
Validation Group 2 N = 
201
Prevalence = 11%
SteatoTest 0.30 1.00 (22/22) 0.56 (100/179) 0.22 (22/101) 1.00 (100/100)
SteatoTest 0.50 0.68 (15/22) 0.79 (142/179) 0.29 (15/52) 0.95 (142/149)
SteatoTest 0.70 0.32 (7/22) 0.92 (165/179) 0.33 (7/21) 0.92 (165/180)
GGT 50 IU/L 0.09 (2/22) 0.97 (174/179) 0.29 (2/7) 0.90 (174/194)
ALT 50 IU/L 0.05 (1/22) 0.98 (176/179) 0.25 (1/3) 0.89 (176/197)
Validation Group 3 N = 
62
Prevalence = 94%
SteatoTest 0.30 0.85 (49/58) 0.00 (0/4) 0.93 (49/53) 0.00 (0/9)
SteatoTest 0.50 0.62 (36/58) 1.00 (4/4) 1.00 (36/36) 0.15 (4/26)
SteatoTest 0.70 0.40 (23/58) 1.00 (4/4) 1.00 (23/23) 0.10 (4/39)
GGT 50 IU/L 0.90 (52/58) 0.00 (0/4) 0.93 (52/56) 0.00 (0/6)
ALT 50 IU/L 0.53 (31/58) 0.75 (3/4) 0.97 (31/32) 0.10 (3/30)
All Groups N = 884 Prevalence = 30%
SteatoTest 0.30 0.90 (238/265) 0.54 (336/619) 0.46 (238/521) 0.93 (336/363)
SteatoTest 0.50 0.72 (190/265) 0.75 (466/619) 0.55 (190/343) 0.86 (466/541)
SteatoTest 0.70 0.46 (122/265) 0.88 (546/619) 0.63 (122/195) 0.79 (546/689)
GGT 50 IU/L 0.66 (174/265) 0.76 (468/619) 0.54 (174/325) 0.84 (468/559)
ALT 50 IU/L 0.72 (185/265) 0.62 (382/619) 0.44 (185/422) 0.83 (382/462)
Table 3: Values {Area under the ROC curves (AUROCs)} of SteatoTest, GGT and ALT for the diagnosis of steatosis greater than 5%, 
in both training and validation groups.
Diagnostic panel Training Group 
AUROC (se)
Validation Group 1 
– HCV before 
treatment
Validation Group 2 
– HCV sustained 
responders
Validation Group 3 
– Alcoholic liver 
disease
All groups
N = 310 N = 171 N = 201 N = 62 N = 884
SteatoTest 0.79 (0.03)* 0.80 (0.04)£ 0.86 (0.03) $ 0.72 (0.05)** 0.80 (0.02) ££
GGT 0.66 (0.03) 0.67 (0.05) 0.74 (0.05) 0.50 (0.09) 0.66 (0.02)
ALT 0.58 (0.03) 0.62 (0.05) 0.79 (0.04) 0.66 (0.07) 0.61 (0.02)
* – Higher than GGT (P < 0.0001) and ALT (P < 0.0001); £ – Higher than GGT (P = 0.007) and ALT (P < 0.0001); $ – Higher than GGT (P = 0.02); 
** – Higher than GGT (P = 0.002); ££ Higher than GGT (P < 0.0001) and ALT (P < 0.0001).Page 7 of 14
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Relationship between ST, and the grade of liver steatosis in the integrated database combining controls, training group and val-idation groupsFigure 3
Relationship between ST, and the grade of liver steatosis in the integrated database combining controls, train-
ing group and validation groups. Failure of the shaded boxes to overlap indicates statistical significance between medians 
(P < 0.05). There was a significant difference between all grades by the Tukey-Kramer multiple comparison test for all pairwise 
differences between means (P < 0.05). For GGT and ALT, there was no significant difference between S0 and S1 and between 
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Comparative Hepatology 2005, 4:10 http://www.comparative-hepatology.com/content/4/1/10(Table 3), triglycerides 0.63 (0.02), BMI 0.61 (0.02), glu-
cose 0.61 (0.02), bilirubin 0.60 (0.02), ApoA1 0.56
(0.02), A2M 0.56 (0.02) and cholesterol 0.53 (0.02) – all
P values < 0.03.
A cut-off of 0.30 had 90% sensibility and a cut-off of 0.70
had 88% specificity permitting to achieve useful predic-
tive values for steatosis grade 2–4, 93% negative predictive
value (NPV) and 63% positive predictive value (PPV) for
a steatosis prevalence of 30% (Table 4). The 90% specifi-
city was obtained for a 0.72 cut-off with a corresponding
63% PPV. The overall percentage of patients classified
with at least 90% sensitivity or 90% specificity was 59%
(363+156/884).
Among the 744 patients with biopsy, for the diagnosis of
steatosis 3–4, the ST AUROC was 0.79 (0.02), signifi-
cantly higher than GGT 0.74 (0.02) (P = 0.03), and ALT
was 0.71 (0.02) (P = 0.007). The 90% sensitivity was
obtained for a 0.32 cut-off; the 90% specificity was
obtained for a 0.81 cut-off.
Conversion between SteatoTest results and the 
corresponding steatosis grade
ST is a continuous linear biochemical assessment of stea-
tosis grade. It provides a numerical quantitative estimate
of liver steatosis ranging from 0.00 to 1.00, corresponding
to a steatosis scoring system of grades S0 to S4. Among the
140 controls, the median ST value (± SE) was 0.08 ± 0.004
(95th percentile, 0.23). Among the 744 patients with liver
biopsy, the ST conversion was 0.000 – 0.3000 for S0;
0.3001 – 0.3800 for S0-S1; 0.3801 – 0.4800 for S1; 0.4801
– 0.5700 for S1-S2; 0.5701 – 0.6700 for S2; 0.6701 –
0.6900 for S2-S3S4; and 0.6901 – 1.000 for S3-S4.
Steatosis at Ultrasonography and SteatoTest
Ultrasonography has been preformed together with ST
and biopsy in 304 patients. Concordance between steato-
sis diagnosed, at ultrasonography and at biopsy, was
lower (kappa coefficient = 0.32 ± 0.05) than the concord-
ance with ST (at 0.50 cut-off, kappa = 0.44 ± 0.06; P =
0.02), as well as lower AUROC 0.65 ± 0.03 for ultrasonog-
raphy versus 0.78 ± 0.03 for ST (P = 0.001). The ST values
according to the presence of histological and radiological
steatosis are given in Table 5.
Sensitivity analyses
A total of 635 (85%) patients had a time lapse between
biopsy and serum smaller than one month. The AUROC
of ST was similar in those patients (0.77, 95% CI 0.73–
0.80) than in the 109 (15%) patients with greater lapse
(0.82, 95% CI 0.72–0.89; P = 0.36). A total of 670 (78%)
patients had a biopsy sample length smaller than 20 mm.
The AUROC of ST was slightly smaller in those patients
(0.76, 95% CI 0.71–0.79) than in the 161 (15%) patients
with greater sample (0.82, 95% CI 0.74–0.88; P = 0.10).
Discussion
Our results highlight the utility of a new panel of bio-
chemical markers (ST) for the prediction of steatosis of
different origins. A cut-off of 0.30 had 90% sensibility and
a cut-off of 0.72 had 90% specificity permitting to achieve
useful predictive value, 93% NPV and 63% PPV for a stea-
tosis prevalence of 30%. These predictive values are far
from perfection, particularly for PPV; however, already
predictive and significantly higher than those of previous
usual markers GGT, ALT and ultrasonography, as demon-
strated by the increase of AUROCs. This benefit was
observed for the most frequent chronic liver diseases:
chronic viral hepatitis, and alcoholic and non-alcoholic
fatty liver diseases.
We have not identified any reports of a single or a combi-
nation of biomarkers with accurate value for the diagnosis
of steatosis in different chronic liver diseases. Marceau et
al observed in 551 severely obese patients with liver
biopsy that steatosis was associated with male gender, age,
BMI, waist/hip ratio, diabetes, systolic blood pressure,
fasting blood sugar, triglycerides, and non-HDL choles-
terol, but no diagnostic algorithm was provided [29].
Papadia et al. [30] observed in 1000 obese patients an
association between steatosis and AST, ALT, AST/ALT
ratio, body weight, waist/hip ratio, serum glucose, serum
triglycerides, BMI, GGT, age, and unconjugated bilirubin
using regression analysis [30]. No panel was constructed
and they concluded that no reliable biochemical marker
could identify patients with severe steatosis with sufficient
sensitivity for avoiding liver biopsy. Loguercio et al. [31]
observed that in 305 patients with abnormal GGT or ALT,
age, ferritin and tissue 4-hydroxynonenal were associated
with steatosis. On multivariate analysis, no single factor
was found to be an independent predictor [31].
Table 5: SteatoTest value according to presence of liver steatosis greater than 5% at liver biopsy, and according to presence at 
ultrasonography.
No steatosis at biopsy Steatosis at biopsy Significance
No steatosis at 
ultrasonography
N = 143, ST = 0.37± 0.02 N = 74, ST = 0.55± 0.02 < 0.0001
Steatosis at ultrasonography N = 25, ST = 0.47± 0.04 N = 62, ST = 0.70± 0.03 < 0.0001
Significance 0.01 < 0.0001Page 9 of 14
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to the discriminant values of its different components.
The most striking observation was that the combination
of 12 parameters allowed a very significant increase in the
diagnostic values of isolated GGT or ALT. The diagnostic
value of ALT was better than that of GGT, as assessed by
AUROCs in all the different groups. This is surprising as
an elevated GGT is generally thought to be a serum marker
of steatosis and elevated transaminases to be a marker of
NASH. A better association between ALT and steatosis ver-
sus GGT and steatosis has also been observed using proton
magnetic resonance imaging [32].
The diagnostic values of GGT, ALT, triglycerides, choles-
terol, glucose and BMI were expected, because they had
been previously associated with steatosis of different ori-
gins [3,29,31]. Those biomarkers are also associated with
insulin resistance and triglyceride deposition in the liver
[6]. ApoA1 is highly associated with HDL-cholesterol and
a negative association was also expected with steatosis
[29]. The advantage of combining biomarkers of steatosis
and those more specific for fibrosis such as A2M, hap-
toglobin and bilirubin is to adjust the predictive values
according to the associated stage of fibrosis. In the present
study we observed that the grade of steatosis in patients
with extensive fibrosis was significantly lower than in
patients without extensive fibrosis (data not shown).
Our study has several limitations that must be acknowl-
edged. Firstly, despite the use of prospective cohorts of
patients, our study was not a classical prospective study.
The validation groups consisted of previously studied
groups of patients: groups 1 and 2 were from a prospective
randomized trial with a previous publication on steatosis
[33], and group 3 was a prospective cohort of patients
with alcoholic liver disease from a study which had been
published for validation of fibrosis biomarkers [26].
There were three different pathologists but very skilled in
these scoring systems and expert in variability studies. The
analyses of histological specimens and biochemical mark-
ers were performed blindly, and the recommended pre-
analytical and analytical procedures were respected for
most of the components. The analytical variability of cho-
lesterol, triglycerides and glucose should be assessed.
A second limitation was the relatively small number of
patients with grade 3 and 4 steatosis. We observed a non-
significant difference between ST medians, 0.70 for grade
3 versus 0.75 for grade 4. Due to the small sample size of
patients with grade 3–4 steatosis in the validation groups,
further studies should be performed in order to determine
whether ST could discriminate between patients with
marked steatosis (between 30 and 66%) and those with
severe steatosis (over 66%). Grade 3 and 4 steatosis is
more frequent in patients with NAFLD and further studies
must be performed in these patients.
In patients with NAFLD, a liver biopsy is more usually
obtained for identifying additional features of steatohep-
atitis (hepatocellular ballooning, lobular inflammation,
Mallory's hyaline) which may be associated with and/or
predictive for the development of pericellular and/or per-
iportal fibrosis. FT has been already validated for the diag-
nosis of fibrosis in NAFLD [27] and ALD [26]. Studies on
biomarkers of steatohepatitis (NashTest, AshTest) are also
in progress (personal communication of Thierry Poy-
nard). Combination of those non-invasive markers
should help the physician in the management of NAFLD
and ALD.
A third limitation was not having compared prospectively
the serum biomarkers with imaging techniques such as
ultrasonography [28,32,34] and proton magnetic reso-
nance imaging [35]. In the retrospective analysis of the
training population, we observed that ST had a higher
diagnostic value than the routine ultrasonography with
higher AUROCs. It has been already observed that the sen-
sitivity of ultrasonography is low in obese patients [36] for
the diagnosis of steatosis. Proton magnetic resonance
imaging is expensive; nevertheless, a validation of ST ver-
sus proton magnetic resonance imaging would be quite
interesting.
In contrast with the above mentioned limitations, one
advantage of the present design was the inclusion of het-
erogeneous patients in the training group with different
causes of chronic liver disease as well as the validation of
the diagnostic values in more homogeneous groups. Vali-
dation groups 1 and 3 included very homogeneous
patients, with chronic hepatitis C and ALD, respectively.
The advantage of validation group 2 was the inclusion of
a group of patients clinically and biologically close to a
"normal" population, as these patients are sustained viro-
logic responders and had quasi-normal liver function
tests. This population offered the unique opportunity of
having liver biopsies in subjects with normal profiles –
not possible, for example, in blood donors. The intra and
inter-laboratory variability has been studied for the 6 FT
components and those studies should also be performed
for cholesterol, triglycerides and glucose. We did not find
any significant differences in ST AUROCs according to
ethnicity (data not showed) [37].
As discussed for liver fibrosis, it is also possible that the
limitations of liver biopsy (sampling error and patholo-
gist concordance) did not allow a perfect area under the
curve to be reached [38]. In hepatitis C the ideal gold
standard would be at least a 40 mm length biopsy sample.
Bedossa et al. [18] recommend, at least, 25 mm; but thePage 10 of 14
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hepatitis C, 18 % of discordance in fibrosis staging has
been attributed to liver biopsy failures (mainly due to
small sample size) and 2% to FT (due to hemolysis,
inflammation and Gilbert's syndrome) [38]. For liver stea-
tosis, there is also a sampling variability with discordance
in 22% of patients [19]. In the present study, we observed
discordance between steatosis assessed by ST and that
assessed by biopsy, in 10% to 21% according to patient's
group. Several discordant cases seem to be attributable to
biopsy (false negatives of biopsy) as the quality was poor
and, at least, one metabolic risk factor was present. Signif-
icant discordance was more often observed in patients
with extensive fibrosis. We previously suspected a risk of
greater variability in assessing fibrosis when steatosis was
present but the inverse could be also true: a greater varia-
bility in assessing steatosis in case of cirrhotic or pre-cir-
rhotic stages [38].
ST is not a perfect diagnostic tool, but has several advan-
tages over other proposed strategies for steatosis manage-
ment. The 12 components of ST are readily available.
FibroTest-ActiTest is now available in several different
countries, including the USA (FibroSure™), with a quality
charter for laboratories for reducing inter-laboratory vari-
ability [23,30,38,39]. As demonstrated in the present
study, ST allowed the assessment of steatosis in patients
with paired biopsy. This could be very useful for the fol-
low-up of patients. This has been validated in HCV
patients before and after treatment and should be vali-
dated in patients with ALD and NAFLD with paired biop-
sies.
There is no specific approved treatment for steatosis. Rec-
ommendations depend on the cause. There is wide agree-
ment for the cessation of alcohol consumption in heavy
drinkers, weight reduction in obese patients, and the treat-
ment of diabetes and hyperlipidemia [1-4]. In patients
with chronic hepatitis C and genotype 3, 50% of the
patients treated and who have a sustained virologic
response have a disappearance of liver steatosis at the sec-
ond biopsy [33]. Bellentani et al. [3] recommended that
subjects with elevated ALT or GGT should be screened for
steatosis using hepatic ultrasonography. They suggested
that the demonstration of hepatic steatosis should
prompt a reduction of caloric and alcohol intake and fol-
low-up with both ultrasonography and biochemical tests.
When clinically indicated, a liver biopsy for assessing the
degree of fibrosis and inflammation could be performed.
Conclusion
According to the low predictive values of ALT, GGT and
ultrasonography, as well as the risk and the variability of
liver biopsy, the previous strategy could be improved by
using better biomarkers of steatosis, such as ST, combined
with biomarkers of fibrosis, such as FibroTest-Fibrosure,
and with biomarkers of steatohepatitis. The cost will be
probably similar to the price of FibroTest-Fibrosure (cur-
rently around 100 €) and cheaper than biopsy or proton
magnetic resonance imaging. This new strategy will likely
reduce the indications of liver biopsy. Prospective studies
are needed to confirm those results and to support the
general use of this new biomarker.
Methods
Study population
Consecutive patients who were included were those with
an available serum sample, a liver biopsy, and a time
interval between serum sampling and biopsy of less than
three months (Figure 1).
Training group (mixed liver diseases)
These patients were retrospectively included for this spe-
cific analysis, but had been analyzed in previous prospec-
tive validation studies of FT between September 2000 and
August 2004 [23,24,27,38]. All were patients hospitalized
in the of Hepato-Gastroenterology department of Groupe
Hospitalier Pitié-Salpêtrière for NAFLD, hepatitis C and B,
and ALD.
Validation group one (hepatitis C)
These patients were retrospectively analyzed from a study
of steatosis in patients with chronic hepatitis C [33]. For
this purpose, previously non-treated patients of a prospec-
tive multicentre randomized trial of pegylated-Interferon
and ribavirin were included. The biomarkers and the
biopsy results at baseline were used.
Validation group two (former hepatitis C, with 
undetectable HCV)
These patients were those from the patients of the same
randomized trial [33] who had been "cured" – they had a
sustained virologic response, with undetectable HCV
RNA, at the end of treatment and 24 weeks after the end
of treatment. The biomarkers and the biopsy results per-
formed 24 weeks after the end of treatment were used.
This group can be considered to be a validation group of
non-viral steatosis because possible viral steatosis had
been cured by the treatment [33].
Validation group three (ALD)
These patients were retrospectively included for this spe-
cific analysis but had been prospectively included
between 1998 and 2000 in a cohort of alcoholic patients
for which one primary endpoint was the identification of
biochemical markers. The details of this cohort have been
recently published in a validation study of FT [26]. All
were patients hospitalized in the Hepato-Gastroenterol-
ogy Department of Hôpital Antoine Béclère, for complica-
tions of alcoholic liver disease.Page 11 of 14
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Non-inclusion criteria included non-available serum,
non-available biopsies and biopsy and serum samples
which had been collected more than 3 months apart (Fig-
ure 1). Patient characteristics are given in Table 1.
Control groups
This included a group of, apparently, healthy volunteers
who had been previously included in a validation study of
FT, in fasting and non-fasting conditions [39]. A group of
non-fasting blood donors were also prospectively
included.
Histologic analysis
Common rules were applied to the different groups. Liver
biopsy specimens were processed using standard tech-
niques. Patients with viral hepatitis were evaluated for
fibrosis and grade of activity according to the METAVIR
scoring system, for which reproducibility had previously
been established [40]. Patients with ALD and NAFLD were
evaluated with modified staging and grading scores [41-
44]. Fibrosis was staged on a scale of 0 to 4: F0 – no fibro-
sis; F1 – portal fibrosis or perivenular fibrosis without
septa; F2 – few septa; F3 – numerous septa without cirrho-
sis; and F4 – cirrhosis. Activity (the intensity of necroin-
flammatory activity mostly based on necrosis) was scored
as follows: A0 – no histologic activity; A1 – mild activity;
A2 – moderate activity; and A3 – severe activity. Steatosis
was scored from 0 to 4 with a four grades scoring system
from S0 to S4: S0 – no steatosis; S1 – mild 1 to 5% (% of
hepatocytes containing visible macrovesicular steatosis);
S2 – moderate 6 to 32%; S3 – marked 33 to 66%; and S4
– severe 67 to 100% [33]. The main histological criterion
was the presence of steatosis grade 2–4 (between 6 to
100%). A single pathologist per group, unaware of patient
characteristics, analyzed the histological features (Frederic
Charlotte for the training group, Zack Goodman for vali-
dation groups 1 and 2, and Dominique Capron for valida-
tion group 3).
Serum biochemical markers – New biomarker of steatosis
A new panel (ST, Biopredictive, Paris, France, patent pend-
ing) was constructed in the training group combining the
6 components of the FibroTest-ActiTest (patented artifi-
cial intelligence algorithm USPTO 6,631,330) adjusted
for age, gender and BMI, plus serum glucose, triglycerides
and cholesterol. ST scores of range from zero to 1.00, with
higher scores indicating a greater probability of significant
lesions. FT and AT (Biopredictive, Paris, France; Fibro-
SURE LabCorp, Burlington, NC, USA) were determined as
has been previously published [23,38,39]. The published
recommended pre-analytical and analytical procedures
were used [23,38,39,45,46]. In the training and control
groups, GGT, ALT, serum glucose, triglycerides, choles-
terol, and total bilirubin were measured by Hitachi 917
analyzer or Modular DP analyzers (both Roche Diagnos-
tics Mannheim, Germany) using the manufacturer's rea-
gents. A2M, ApoA1, and haptoglobin were measured
using an automatic nephelemeter BNII (Dade Behring;
Marburg, Germany). In validation groups 1 and 2, GGT,
ALT, serum glucose, triglycerides, cholesterol, and total
bilirubin were measured using Hitachi 747 or 911 (Roche
Diagnostics, Indianapolis, IN, USA) with the manufac-
turer's reagents. ApoA1, A2M and haptoglobin were deter-
mined in serum samples using an automatic
nephelometer BNII (Dade Behring, Marburg, Germany).
In validation group 3, ALT, GGT, serum glucose, triglycer-
ides, cholesterol, total bilirubin and haptoglobin were
measured by autoanalyzer (Olympus AU 640 Automate)
using manufacturer's reagents (Olympus, Rungis, France);
A2M and ApoA1 were measured using an automatic neph-
elometer (BNII, Dade Behring, Marburg, Germany). All
coefficients of variation assays were lower than 10%.
Imaging
Ultrasonography reports have been retrospectively ana-
lyzed for the presence or absence of radiological steatosis
in the validation group, blindly to histological and bio-
chemical data.
Statistical analyses
The primary outcome was grade 2, 3 or 4 of steatosis
(S2S3S4). The cause of discordance between the presence
of S2S3S4 steatosis, as predicted by biochemical markers
and biopsy was attributed according to respective risk fac-
tors of failure, as previously detailed [38]. Significant dis-
cordance was defined as discordance in predicting grades
S2S3S4 and a 30% or greater difference in steatosis per-
centage, as predicted by ST or as observed in the biopsy
sample. Risk factors of ST failure were hemolysis, Gilbert's
disease, acute inflammation and extra-hepatic cholestasis.
Risk factors of biopsy failure were biopsy size (less than 25
mm) and fragmentation (more than one fragment). Fail-
ure attributable to biopsy (false negative) was suspected
when the biopsy length was less than 15 mm and frag-
mented with the additional presence of, at least, one met-
abolic risk factor.
Statistical analysis used Fisher's exact test, the chi-square
test, Student's t-test and the Mann-Whitney test; variance
analysis used the Bonferroni all-pair wise and the Tukey-
Kramer multiple-comparison tests to take into account
the multiple comparisons, and multiple logistic regres-
sion the for multivariate analysis [47]. The diagnostic val-
ues of the markers were assessed using sensitivities,
specificities, PPVs and NPVs and AUROCs [47]. Corre-
sponding steatosis grades were calculated from median ST
scores and 95% confidence intervals observed in 744
patients and 140 controls. AUROCs were calculated using
the empirical non-parametric method according toPage 12 of 14
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Zhou et al. [49]. The binomial approach was used only
when the sample size population was less than 30 [50].
For all analyses, two-sided statistical tests were used; a P-
value of 0.05 or less was considered significant. Number
Cruncher Statistical Systems 2003 software (NCSS, Kay-
sville, Utah, USA) was used for all analyses [47].
A sensitivity analysis was also performed for determining
the accuracy of the markers for the primary outcomes
according to biopsy sample size (less than 20 mm or
more) and to time lapse between serum and biopsy (less
than 4 weeks or more).
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